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Background/aim: We aimed to assess the association between retinal vascular caliber (RVC) scores and disease activity in rheumatoid
arthritis (RA) patients.
Materials and methods: Forty-seven RA patients, 32 systemic lupus erythematosus (SLE) patients, and 45 healthy people were enrolled.
RA and SLE patients were subdivided into groups according to C-reactive protein (CRP) levels. RA patients were also grouped according
to Disease Activity Score-28 (DAS-28). Fundus photography was performed for all patients. RVC was summarized as the central retinal
artery and vein equivalents (CRAE and CRVE).
Results: Mean CRVE for RA patients was 213.3 ± 17.8 µm compared with 209.2 ± 14.1 µm for SLE and 217.5 ± 26.2 µm for the control
group (P = 0.17). RVC scores did not differ between the CRP-high and CRP-low groups. As the RA disease activity increased, the
widening of CRVE became more prominent and statistically significant. When the DAS-28 > 5.1 (CRVE, 220.4 (211.8–246.5) µm) group
and DAS-28 ≤ 3.2 (CRVE, 214.4 (172.4–242.3) µm) group were compared, statistical significance was more pronounced (P = 0.03) than
when comparing the DAS-28 > 3.2 and DAS-28 ≤ 3.2 groups (P = 0.05).
Conclusion: CRVE, which reflects systemic inflammation and possibly increased cardiovascular risk, was significantly increased in
active RA patients. The association between retinal venular widening and disease activity, regardless of CRP, may be a sign that RArelated inflammation may have systemic vascular effects even with normal levels of CRP.
Key words: Rheumatoid arthritis, retinal vascular caliber, microvascular health, cardiovascular risk

1. Introduction
Cardiovascular diseases (CVDs) are the leading cause of
death worldwide (1). Microvascular disease plays a role in
the early development of CVDs and can be reversed. For
this reason, strategies for improving microvascular health
are a favorite subject for researchers (2,3). Rheumatoid
arthritis (RA) is known to be associated with endothelial
dysfunction and a greater risk of cardiovascular (CV)
morbidity and mortality (4–6). The excess of CV morbidity
and mortality in RA patients cannot be explained by
traditional risk factors. There is much evidence that
chronic inflammation and autoimmunity may cause this
increased risk (2,4,7).
Assessment of microvascular structure is valuable in
CV risk analysis in RA patients (8). Recent technological
advances in high-resolution digital photography and
image processing software programs have enabled the

quantitative and reproducible measurement of various
changes in retinal vasculature (9). The concept of retinal
vascular caliber (RVC) emerged after this innovation
as a noninvasive tool for assessing microcirculation.
Independent of traditional risk factors, RVC widening
has been found to be related to inflammation, endothelial
dysfunction, and increased risk of coronary heart disease,
stroke, and CV mortality (10). Epidemiological studies
have shown that RVC is a cardiovascular event predictor
(11–13). Demonstrating the association between RA
disease activity and RVC may provide evidence of the
increased CV risk in RA, which may be reversible with
effective treatment (14).
A study conducted in 2011 showed that patients
diagnosed with RA according to the criteria of 1987 had
wider RVC than the normal population and this widening
was associated with disease activity (15). In an article
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published in 2016, the reduction of RVC was proved in the
case of suppression of inflammation in RA patients (16).
With this background, the objective of this study was to
assess RVC scores in RA patients and compare them with
systemic lupus erythematosus (SLE) patients and a healthy
control group. The second objective was to investigate the
association and correlation between RVC scores and RA
disease activity indexes at the beginning and at follow-up.
2. Materials and methods
2.1. Study population
Between July 2014 and January 2015, 49 consecutive RA
patients as defined by the 2010 ACR-EULAR criteria (17)
were enrolled in this prospective observational study.
Thirty-two SLE patients as defined by the 1997 ACR
criteria (18) and 45 healthy people who had already been
referred to the department of eye diseases and had no
known medical issues other than refractive error of the
eyes constituted the comparison groups. Exclusion criteria
were acute glaucoma, inability to provide informed
consent, and ungradable retinal photographs. Two RA
patients were excluded from the research because of
glaucoma and ungradable retinal photographs.
2.2. Collecting data
Demographic data, medical history, current medications,
physical measurements, and serum biochemical
parameters of all participants were recorded. All
traditional CVD risk factors such as diabetes mellitus,
hypertension, hyperlipidemia, and smoking status were
noted. Diabetes was defined as fasting serum glucose level
of ≥126 mg/dL or HbA1c of ≥6.5%, or current antidiabetic
drug use. Hypertension and hyperlipidemia were defined
by the use of antihypertensive or antilipidemic drugs or
current guideline recommendations (19,20), and patients’
statements were used to determine hyperlipidemia in
the event that patients’ previous lipid levels could not be
obtained. Smoking status was defined as active based on
smoking within 5 years and packs per year. Body mass
index (BMI) was calculated for each individual. Patients
were divided into groups with BMI of 18.5–24.9 as normal,
25–29.9 as overweight, and ≥30 as obese.
2.3. Outcome measures
2.3.1. Rheumatologic assessments
Tender Joint Count 28 (TJC), Swollen Joint Count 28 (SJC),
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and patient global assessment (visual analog scale
of 0–100 mm) values were recorded at baseline. Disease
Activity Score 28 (DAS-28) was calculated to assess
disease activity (21,22). DAS-28 of >5.1 indicates high
disease activity whereas DAS-28 of <3.2 indicates low
disease activity (23). Functional status was evaluated by
the Health Assessment Questionnaire-Disability Index
(HAQ-DI) (24).

RA patients were invited for reevaluation within 3–6
months. Clinical and biochemical assessments and DAS28 and HAQ-DI scores were measured and recorded again.
RA and SLE patients with known CRP values were
divided into 2 groups with a CRP cutoff value of 0.8 mg/dL
for comparison (reference value).
2.3.2. Retinal vascular assessments
Digital retina photographs of all individuals involved in
the study were taken with a nonmydriatic 30° digital color
fundus camera (Zeiss FF450 IR+) with a standardized
method (9) and stored in the Zeiss Visupac System. Retinal
photographs of RA patients were recorded again at the
second visit.
RVC was measured by an experienced retina specialist
who did not know the characteristics of the participants
using the standardized computer-assisted semiautomated
IVAN software (University of Wisconsin, USA). All retinal
vessels within a 0.5–1 disc diameter of the optic disc margin
were measured. Measurements from the six largest retinal
arterioles and venules were summarized as the central
retinal arteriolar equivalent (CRAE) and central retinal
venular equivalent (CRVE) using the Parr-Hubbard–
Knudtson formula (25) (Figure).
The study was approved by the Hacettepe University
Health Ethics Committee and was conducted in accordance
with the Declaration of Helsinki. Written informed consent
was obtained prior to recruitment.
2.4. Statistical analysis
The data were analysed with SPSS 21.0 for Windows,
provided by Hacettepe University. Distribution of numerical
variables was examined visually (histogram and probability
graphs) and by analytical methods (Kolmogorov–Smirnov
and Shapiro–Wilk tests). For univariate association,
parametric continuous variables were examined with the
Student t-test and nonparametric ones with the Mann–
Whitney U test. ANOVA or K-independent samples tests
were used according to distribution for triple group analysis.
The presentation of the data was done in accordance to the
distribution of variables. Normally distributed variables are
presented as mean ± standard deviation while nonnormally
distributed variables are presented as median (min–max).
Exceptions are noted in the tables. Nominal data were
compared with chi-square or Fisher tests. Correlation
analyses were done with Pearson or Spearman correlation
tests according to suitability. P < 0.05 was considered as a
statistically significant result.
3. Results
3.1. Patients’ demographics and comparison of retinal
caliber between the groups
3.1.1. Study population
We enrolled 47 RA patients comprising 39 females (83%)
and 8 males. The mean age was 52.0 ± 11.9 years and the
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Figure. Example of calculating RVC scores with IVAN software.

median disease duration was 8.3 years (0–30 years). Four
of the RA patients (8.5%) had diabetes mellitus, 19 (40.4%)
had hypertension, and 9 (19.1%) had hyperlipidemia.
Nineteen (40.4%) of the RA patients had smoked previously,
while 14 (29.8%) of them were actively smoking or had a
history of smoking during the last 5 years. The mean BMI
of the patients was 27.9 ± 5 and 29.7% of RA patients were
obese. SLE patients were younger (P = 0.01). There was a
statistically significant difference between the RA and SLE
groups in terms of CRP (P = 0.05). Although three of the
SLE patients had renal involvement in past, the glomerular
filtration rate values of all patients were within the normal
range at the time of the study and none of the patients
had chronic renal disease (creatinine values of the control
group are unknown). There was no statistical significant
difference between the groups in terms of instantaneous
blood pressure values. There was no difference in terms of
other parameters between the groups (Table 1).
3.1.2. Rheumatologic assessments
The clinical characteristics determined at the initial
evaluation of RA patients are shown in Table 2. When
we classified our RA patients according to the DAS-28,
15 (32%) patients were in remission, whereas 7 (15%)
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had low, 15 (32%) had moderate, and 10 (21%) had high
disease activity.
3.1.3. Retinal vascular assessments
Patients with RA had a mean CRAE of 147.8 ± 11.7 µm
compared with 148.3 ± 12.8 µm in SLE and 147.4 ± 17.6
µm in the control group (P = 0.97). Their mean CRVE was
213.3 ± 17.8 µm compared with 209.2 ± 14.1 µm in SLE and
217.5 ± 26.2 µm in the control group (P = 0.17) (Table 3).
There was no difference in retinal caliber between patients
with RA and controls. Table 3 compares retinal vascular
assessments of patients with RA, patients with SLE, and
healthy controls. The patient population consisting of
RA and SLE groups (n = 79) was dichotomized into 2
groups with a CRP cutoff value of 0.8 mg/dL. There was
no difference between the CRP-high group (n = 52) and
the CRP-low group (n = 27) in terms of other risk factors,
SLE/RA patient populations, and CRVE and CRAE values.
3.2. Association between rheumatoid arthritis disease
activity and central retinal caliber
Patients were divided into groups according to DAS-28
scores. While there was no difference in demographic
or cardiovascular risk factors between the groups, it was
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Table 1. Comparison of RA, SLE, and control groups.
RA (n = 47)

SLE (n = 32)

Control (n = 47)

P

Age, mean ± SD

52.1 ± 11.9

41.4 ± 14.5

47.2 ± 17.3

0.01

Female, n (%)

39 (83.0)

27 (84.4)

36 (80.0)

0.87

Diabetes, n (%)

4 (8.5)

1 (3.1)

5 (11.1)

0.44

Hypertension, n (%)

19 (40.4)

10 (31.3)

12 (26.7)

0.36

Dyslipidemia, n (%)

9 (19.1)

1 (3.1)

6 (13.3)

0.11

Smoking, n (%)

14 (29.8)

12 (37.5)

13 (28.9)

0.69

BMI, mean ± SD

27.9 ± 5.0

25.8 ± 4.9

26.2 ± 4.6

0.13

CRP, mg/dLc

0.6 (0.1–4.2)

0.4 (0.1–20.6)

n/a

0.05*

a

b

BMI: Body mass index; CRP: C-reactive protein; n/a: not available; RA: rheumatoid arthritis; SLE:
systemic lupus erythematosus; a: 1, b: 2 missing data; c: median and min–max. *: CRP value is only
available for RA and SLE patients. Bold font indicates statistically significant difference.
Table 2. Baseline disease activity parameters of RA patients.
Rheumatologic assessments

Results

Swollen Joint Count (28 joints), median (min–max)

0 (0–8)

Tender Joint Count (28 joints), median (min–max)

2 (0–15)

Patient Global Assessment (0–100 mm), mean ± SD

42 ± 25

DAS-28, mean ± SD

3.6 ± 1.7

HAQ-DI*, mean ± SD

0.57 ± 0.50

CRP, mg/dL, median (min–max)

0.6 (0.1–4.2)

ESR, mm/h, median (min–max)

19 (2–67)

CRP: C-reactive protein; DAS-28: Disease Activity Score-28; ESR: erythrocyte
sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; *:
HAQ-DI score was available for 33 patients.
Table 3. Retinal vascular caliber measurements of RA, SLE, and control groups participating in the study.
RA (n = 47)

SLE (n = 32)

Control (n = 47)

P

CRAE, mean ± SD, µm

147.8 ± 11.7

148.3 ± 12.8

147.4 ± 17.6

0.97

CRVE, mean ± SD, µm

213.3 ± 17.8

209.2 ± 14.1

217.5 ± 26.2

0.17

CRAE: Central retinal arteriolar equivalent; CRVE: central retinal venular equivalent; RA: rheumatoid
arthritis; SLE: systemic lupus erythematosus.

seen that as the disease activity increased, the widening of
CRVE became more prominent and statistically significant.
When the DAS-28 > 5.1 (CRVE, 220.4 (211.8–246.5) µm)
group and DAS-28 ≤ 3.2 (CRVE, 214.4 (172.4–242.3) µm)
groups were compared, statistical significance was more
pronounced (P = 0.03) than that between the DAS-28 > 3.2
(CRVE, 217.7 (160.8–247.2) µm) and DAS-28 ≤ 3.2 groups

(P = 0.05). There was no difference in arteriolar caliber
between patients with RA and controls in any subgroup
analyses (Table 4).
3.3. Serial retinal vascular caliber measurements
Twenty-four (51%) of the 47 RA patients were assessed 5.2
± 2.1 months later at a second visit. The first and second
visit parameters of the patients were not statistically
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Table 4. Retinal vascular caliber values according to various groups defined by DAS-28 score.

CRAE, µm
CRVE, µm

DAS-28 ≤ 3.2 (n = 22)

DAS-28 > 3.2 (n = 25)

P

145.8 (120.8–169.1)

147.8 (123.3–167.6)

0.24

214.4 (172.4–242.3)

217.7(160.8–247.2)

0.05

DAS-28 ≤ 3.2 (n = 22)

DAS-28 > 5.1 (n = 10)

P

CRAE, µm

145.8 (120.8–169.1)

151.4 (146.3–167.6)

0.12

CRVE, µm

214.4 (172.4–242.3)

220.4 (211.8–246.5)

0.03

Bold font represents statistically significant values.

significantly different (Table 5). There was no significant
correlation between the changes of CRAE or CRVE and
DAS-28, CRP, and HAQ scores.
4. Discussion
Few studies have been done in the field of retinal vascular
health and RA. Although some researchers pay attention
to this issue, information on this topic has to be increased.
This study is one of the few studies examining the
association of retinal vascular caliber with disease activity
in patients with RA.
Our study demonstrates the significant association
between retinal venular caliber and disease activity
statistically. As disease activity increases, this association
becomes more prominent. Our study supports previous
cross-sectional studies in this respect (15,26). In addition
to the current literature, our study showed that the CRVE
widens as disease activity increases, independent of CRP
value. Thus, even in cases of normal CRP values, RA may
have systemic microvascular effects, and these effects grow
while disease activity increases.
Based on our results, it is difficult to precisely say that
there is a relationship between the widening of RVC and
future subsequent cardiovascular events in RA patients,
as the RVC change used for giving the hazard ratio in
metaanalysis is large than that for our results. However,
in this context, it is not appropriate to fully interpret
our results according to the metaanalysis. It is known
that larger venules have been associated with increased
subclinical atherosclerosis, higher carotid plaque scores,
and more aortic calcification and they have an independent
role in predicting cardiac events in some populations,
with a higher risk of stroke (12). As a result of all of this,
our findings support the hypothesis that greater disease
activity is associated with greater cardiovascular risk, even
with normal CRP levels.
There was no difference in retinal venular caliber
between the RA, SLE, and control groups. This result can
be explained by the age difference between the groups,
the fact that retinal venules may be wide in SLE patients
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Table 5. The first and second visit parameters of RA patients.
1st visit

2nd visit

DAS-28

3.66 (0.63–6.72)

3.22 (1.18–5.24)

CRP, mg/dL

0.54 (0.12–3.86)

0.45 (0.15–3.04)

CRVE, µm

217.9 (160.81–247.2)

215.5 (160.2–247.8)

CRAE, µm

147.1 (128.7–169.1)

145.7 (120–165.5)

HAQ-DI*

0.2 (0–1.05)

0.05 (0–0.95)

Data are presented as median (min–max). Twenty-four (51%)
of the 47 RA patients attended second visits. CRP: C-reactive
protein; CRAE: central retinal arteriolar equivalent; CRVE:
central retinal venular equivalent; DAS-28: Disease Activity
Score-28; HAQ-DI: Health Assessment Questionnaire-Disability
Index. *: HAQ-DI score was available for 13 patients.

(26), the lack of CRP values for the control group, and the
criteria used to diagnose the RA patients.
There are some methodological differences from other
similar studies. In contrast to others, the ACR-EULAR
2010 criteria were used to diagnose RA in this study.
Disease duration was similar to other studies (15,26).
From this point of view, we may have a patient population
with early diagnosis. Although erosions or deformities
were not noted in any of these studies, there may be fewer
erosions or deformities in our RA patients. Clinical disease
scoring methods are also different. In one study (16), DAS28-CRP was used, whereas in another study only CRP
was used (26). These factors may be the cause of minor
differences between the results of studies.
In one of the previous studies (26), a CRP–CRVE
association was shown. In that study, patients were
dichotomized into groups by a CRP cutoff value of 15
mg/L. When we used this level for our patient population,
only 12 patients had a CRP value greater than 15 mg/L. We
may not have found a CRP–CRVE association because of
the distributional variability of CRP values between these
studies.
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One of the few studies (16) on this subject showed that
there was no difference in RVC during follow-up in stablelow inflammation RA patients, similar to our results.
The strength of our study includes the fact that it is
the first study comparing RA to another rheumatologic
disease and employing the most recent diagnostic criteria.
A follow-up study used a highly reproducible method to
assess retinal vessel size and demonstrated that RVC did
not change in stable patients. This result also indicates
that the measurement-bound bias is minimized. Most
importantly, this is the first study to demonstrate that
CRVE is related to disease activity regardless of CRP level.
The limitations of the study were being cross-sectional
and observational; a small sample size for subgroup
analysis; a lower number of RA patients attending the
second visits; not knowing the CRP, creatinine value, and
lipid profile of the control group; not knowing the lipid
profiles at the time of retinal examination; and not knowing
how many patients were under effective treatment.

Although retinal vascular caliber measurement is a
newly defined method, the number of studies on this topic
is constantly increasing. In these studies, RVC widening
has been shown to be an important clue in determining
cardiovascular risk and predicting CVS events (11–13).
Individuals with larger RVC were found to have a higher
risk of stroke, coronary heart disease, and mortality (10). It
is known that CV mortality is increased in RA patients, and
epidemiological studies show that this mortality increase
is not fully explained by classical risk factors (4). Briefly,
CRVE, which reflects systemic inflammation and possibly
increased CV risk, was significantly increased in active RA
patients. The association between retinal venular widening
and disease activity regardless of CRP may be a sign that
RA-related inflammation may have systemic vascular
effects even with normal levels of CRP.
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